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Background: This work investigates on putative cytotoxic effects in four different 
hepatocellular carcinoma (HCC) cell lines after irradiation with photons or carbon ions 
in combination with new targeted molecular therapy using either Temsirolimus (TEM) or 
Gemcitabine (GEM).
Methods and materials: The HCC cell lines HepG2, Hep3B, HuH7, and PLC were 
cultured and irradiated with photons or carbon ions at the Heidelberg Ion Beam Therapy 
Center using the raster-scanning method. For combination experiments, cell lines were 
first treated with Temsirolimus or GEM before irradiation. Cytotoxicity was measured by 
a clonogenic survival assay. The evaluation of the experiments and the obtained survival 
curves were based on the concept of additivity defined by Steel and Peckham.
results: The results for the combination of carbon ions and both tested systemic sub-
stances TEM and GEM showed independent toxicities in all four cell lines. Supra-additive 
effects were observed in PLC cells for photon irradiation combined either with TEM or 
GEM and in HuH7 cells for the combination of photons with TEM.
conclusion: Addition of targeted therapy substances Temsirolimus and GEM to photon 
irradiation showed additive cytotoxicity in HCC cell lines, whereas independent toxici-
ties where reached by the combination of carbon ions to these substances. It can be 
assumed that combining 12C with systemic substances only has independent effects 
because heavy ions cause direct damage because of their high-LET character resulting 
in complex and clustered double-strand breaks. Nonetheless, further investigations are 
warranted in order to determine whether addition of systemic therapy allows a reduction 
of radiation doses in combination therapy. This could possibly lead to better responses 
and tolerances in patients with HCC.
Keywords: carbon ion irradiation, hepatocellular carcinoma, Temsirolimus, gemcitabine, combined modality 
treatment
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inTrODUcTiOn
Hepatocellular carcinoma (HCC) is the fifth most common 
cancer worldwide and makes up the second common cause 
of cancer-related death in males. In women, it is the seventh 
most common cancer worldwide and the sixth leading cause 
of death. Because of an increasing incidence of HCC and due 
to a rising incidence of hepatitis C and liver cirrhosis (1), it 
has gained clinical interest, especially in areas like Europe 
and North America, which have had low rates of the disease 
yet. HCC is difficult to treat, because at initial presentation 
the disease is multifocal or locally advanced. The challenge 
of every applied treatment is to preserve sufficient rest liver 
function.
At this point, there are several therapy modalities, mainly 
surgical excision or liver transplantation, which provide 
the most mature outcome data (2, 3). However, there is a 
limit to a surgical therapy for HCC, because patients often 
present with a poor liver function because of an underly-
ing cirrhosis, macro-vascular tumor invasion or advanced 
stage of the disease. Furthermore, interventional treatments, 
e.g., transarterial chemo-embolization, radio-frequency abla-
tion, and radiotherapy (RT) are available, but data for these 
modalities are still sparse and to date no randomized trials are 
available.
In the past, RT only played a minor role in the treatment of 
liver malignancies, because of the livers low tolerance to radia-
tion and the challenge to deliver high-dose irradiation to the 
target while sparing the uninvolved tissue (4). Due to several 
technological advancements such as highly conformal RT and 
particle-beam therapy (PBT), there is a more precise irradiation 
application to the tumor and a better surveillance of the beam 
while treatment (5, 6). In 1960s, irradiation with heavy ions has 
been launched in clinical practice and is now established for 
several cancer modalities. There is a clear physical advantage of 
particle beams—compared to photon irradiation—that consists 
in a deeper dose gradient due to an inverted dose profile provided 
by a spread-out Bragg peak. Carbon ion beams show a higher 
relative biological effectiveness (RBE), which therefore can 
overcome relative radio-resistance induced by hypoxia through 
induction of clustered DNA double-strand breaks (DSBs). This 
bears the hope of an improvement in treating HCC and other 
tumor entities (7).
The application of systemic chemotherapy to HCC has had 
limited impact on treatment of HCC. Only the multi-kinase 
inhibitor Sorafenib has been approved as an agent for standard 
therapy of advanced HCC (8). Nevertheless, newer targeted 
biological therapies like Temsirolimus (TEM) interfering 
with crucial molecular pathways in hepatocarcinogenesis 
are investigated and need to be evaluated in the future (9). 
Another systemic drug is Gemcitabine (GEM) showing 
promising results in different trials with hepatobiliary tumor 
entities but needs to be tested explicitly for HCC (10–12). 
This work is concerned with the evaluation of two systemic 
drugs, TEM, and GEM in four different HCC cell lines, 
especially in combination with photon and carbon ion (12C) 
irradiation.
MaTerials anD MeThODs
cell culture
Four human HCC cell lines, Hep3B, HepG2, PLC, and HuH7 
were used. Hep3B, HepG2, and PLC had been obtained from the 
American Type Culture Collection (ATCC, Manassas, VA, USA), 
whereas HUH7 had been obtained from the Japanese Collection 
of Research Bioresources Cell Bank (JCRB Cell Bank, Japan). 
HuH7, Hep3B, and PLC were grown in Dulbecco’s Modified 
Eagle Medium (Biochrom, Berlin, Germany), whereas HepG2 
was maintained in RPMI 1640 medium (Biochrom, Berlin, 
Germany). Both media were supplemented with 10% heat-
inactivated fetal bovine serum (Biochrom, Berlin, Germany) and 
1% penicillin-streptomycin (Invitrogen, Darmstadt, Germany). 
The cells were stored lying flat in 175  cm2 tissue plastic flasks 
(Falcon, Becton-Dickinson Labware Europe, Le Pont de Claix, 
France) in an incubator at 37°C in humidified air with 5% CO2 
and passaged weekly.
clonogenic assay
The technique applied was the clonogenic assay, which allows the 
biological efficiency to be determined by measuring clonogenic 
cell death. In order to generate reliable results, every experiment 
was performed in triplets three times at independent days. At 
first, a defined and increasing amount of cells, adjusted to the 
increasing doses of irradiation and/or concentration of the drug 
under investigation, were seeded into 25  cm2 flasks (Falcon, 
Becton-Dickinson Labware Europe, Le Pont de Claix, France), 
filled with media and incubated for 24 h. After this 24-h incuba-
tion, the treatment could be performed and afterward the flasks 
were left for several days in the incubator. The number of days for 
incubation was nine. Finally, the flasks could be inspected under 
the microscope for surviving colonies, which are defined as cell 
accumulations containing at least 50 cells per colony. Colony 
counting was performed under the microscope with a threshold 
of minimum 50 cells per colony. From the determined surviving 
fractions, the plating efficiency (PE) and clonogenic survival 
were calculated. These results were used to generate survival 
curves, to define α- and β-parameters and to calculate RBE 
values. SigmaPlot (Systat Software GmbH, Erkrath, Germany) 
non-linear least-squares regression option was used to fit the 
linear-quadratic expression [−ln(S)  =  α*D  +  β*D2] to the 
resulting averaged survival fractions after normalizing plating 
efficiencies to the untreated samples (S is the number of surviv-
ing cell following a dose of D, and α and β are the respective 
sensitivity coefficients).
In order to assess the results in the combination experi-
ments, four terms were adopted from the criteria of addi-
tivity published by Steel and Peckham (13). These terms 
are independent toxicity, additivity, supra-additivity, and 
sub-additivity. The term independent toxicity (additivity) is 
described as the sum of the single effects of each agent used in 
a combination experiment. The expected effect of combination 
of two agents can be presented in an isobologram. Do the 
results of a combination experiment exceed the expected sum 
effects of two single effects, what implies potentiating and/or 
FigUre 1 | Fitted survival curves of hep3B and Plc cells after photon- and carbon ion-irradiation. Abbreviations: 12C, carbon ion irradiation. Error bars 
represent SD.
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radiosensitizing, the term supra-additivity (or synergism) is 
used. Sub-additivity due to inhibition or antagonisms describes 
a response, which is below the expected response of two single 
agents in combination.
irradiation
An X-ray irradiator (XRAD 320 Precision X-ray Inc., North 
Bradford, CT, USA) was used with 1.5 mm Al, 0.25 mm Cu, and 
0.75mm Sn filtration. Irradiation took place with dose rates of 
1.2  Gy/min with a voltage of 320  kV and a current of 20  mA. 
Irradiation of the cell monolayer was performed with doses of 2, 
4, 6, and 8 Gy at room temperature.
Irradiation with 12C was conducted at the Heidelberg 
Ion-Beam Therapy center (HIT) using the raster-scanning 
method (14). To expose the cell monolayer to the middle 
of the extended Bragg peak, the ground of the flasks was 
arranged along a construction with a 3 cm acrylic shield and 
irradiated with a horizontal beamline using the raster-scanning 
technique. Single doses of 0.125, 0.5, 1, 2, and 3  Gy were 
delivered at the experiments with an averaged dose rate of 
TaBle 2 | ic50 values of geM and Temsirolimus for all cell lines.
geM (nM) TeM (nM)
HepG2 20 190
Hep3B 19 210
HuH7 50 0.22
PLC 39 0.4
GEM, Gemcitabine; TEM, Temsirolimus; IC50, half maximal inhibitory concentration.
TaBle 1 | calculated rBe values for 10% cell survival for all cell lines 
after photon- and carbon ion-irradiation.
Photons (gy) 12c (gy) rBe at 10% sF
Hep G2 4.17161 1.34914 3.09
Hep 3B 4.1123 1.17415 3.50
HUH 7 4.56393 1.49346 3.05
PLC 7.05334 1.46768 4.80
12C, carbon ion irradiation; RBE, relative biological effectiveness; SF, surviving fraction.
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0.5  Gy per minute. The spread out of the Bragg peak was 
assured by positioning of a plexi glass device (30-mm thick-
ness) in front of the cell culture flasks. LET of the C12 RT 
was between 122.36 and 136.92 MeV/u and the applied beam 
width measured 7.1–7.8  mm.
reagents
Gemcitabine (Gemzar®, dFdGem) was used in concentrations of 
10, 30, 40, and 50 nM. For combination with RT (photon and 12C) 
concentrations of 10 and 30 nM were applied. Twenty-four hours 
after seeding the cells, the media was replaced with fresh media 
containing the reagents at the appropriate concentration and 
the cells were subsequently irradiated after 4-h incubation time. 
Temsirolimus (Torisel®, CCI-779) experiments were conducted 
on PLC and HuH7 cells with concentrations of 0.01, 0.1, 1, 
and 2  nM, while combination therapy with irradiation took 
place with a concentration of 0.1 nM. Experiments with Hep3B 
and HepG2 were conducted with 500, 750, 1,000, 1,500, and 
2,500 nM. The subsequent combination therapy was performed 
with 750  nM of TEM.
Sensitivity to the anti-tumorigenic effect of both drugs was 
expressed as an IC50 value which represents the drug concentra-
tion causing 50% inhibition of the clonogenic survival. The 
half maximal inhibitory concentration of both substances was 
calculated for all cell lines.
statistical analysis
Data were analyzed using SigmaPlot (Systat Software GmbH, 
Erkrath, Germany). Data are presented as the mean  ±  SE. 
Differences with a p  <  0.05 were considered statistically sig-
nificant. Statistical comparison of mean values in the RBE was 
performed using unpaired two-tailed t-test analysis. Error bars 
included in graphical figures represent SD.
All experiments were performed in accordance with institu-
tional ethical guidelines. This work does not contain any studies 
with human or animal subjects. All cell lines were commercially 
available and experiments were performed according to insti-
tutional and national guidelines. An ethical approval was not 
needed for this type of study.
resUlTs
Photon vs carbon ion irradiation
First, photon and 12C irradiation was performed with all four 
HCC cell lines Hep3B, HepG2, PLC, and HUH7 to determine 
clonogenic survival. Clonogenic survival correlated negatively 
with increasing radiation doses for both RT modalities. The 
average numbers of PE for the cell lines in the control group 
were 8.1% for Hep3B, 6.3% for HepG2, 4.9% for PLC, and 
13.6% for HUH7. The surviving fractions determined were 
used to perform linear-quadratic fits and calculate clonogenic 
survival curves for each cell line in order to compare the 
effectiveness of photon and 12C irradiation. All four cell 
lines showed a dose-dependent suppression of clonogenic 
survival as can be seen by typical shoulder shaped curves. 
The 12C dose-response curves showed a consistently steeper 
decrease of surviving cells with increasing doses compared to 
photons (p ≤  0.01; Figure 1). All survival curves after X-ray 
irradiation follow the linear-quadratic model. However, some 
survival curves after 12C irradiation showed an upward tailing. 
The RBE values were calculated by at the 10%-survival level. 
The results are shown in Table  1. 12C irradiation showed an 
enhanced relative biological effectiveness toward clonogenic 
cell death induction than low-LET irradiation with photons. 
The comparison of RBE values at the 10%-survival level of 
photon and 12C irradiation ranged from 3.05 for HUH7 to 
4.8 for PLC cells.
Treatment with either geM or TeM
Single-modality treatment of all cell lines with TEM or GEM 
led to a reduction of clonogenic survival in a dose-dependent 
manner. Table  2 summarizes calculated IC50 values for both 
substances in all four cell lines. IC50 concentrations for GEM and 
TEM were highest for HuH7 and Hep3B, respectively, and low-
est for Hep3B and Huh7, respectively (Table 2). Figure 2 shows 
the survival curves of Hep3B and PLC cells after treatment with 
GEM or TEM. The surviving fractions determined were used to 
perform linear-quadratic fits and calculate clonogenic survival 
curves for each cell line in order to compare the cytotoxicity of 
GEM and TEM treatment.
combined Treatment
In case of combination experiments with photon RT and TEM 
or GEM, PE values and averaged values were normalized to a 
drug control. Our experiments showed supra-additive cytotoxic 
effects for PLC cells (p ≤  0.01) after irradiation and treatment 
with TEM or GEM (Figures 3 and 4). Supra-additive means that 
the combined effect is caused by lower doses of the two agents 
than is predicted. Furthermore, there were also supra-additive 
effects observed for HuH7 cells in combination of photon RT and 
TEM (p ≤  0.01). All other combinations of drugs and photon 
irradiation showed independent toxicity in Hep3B, HepG2, and 
HUH7 cell lines.
FigUre 2 | Fitted survival curves of hep3B and Plc cells after treatment with gemcitabine (geM) or Temsirolimus. Abbreviations: 12C, carbon ion 
irradiation. Error bars represent SD.
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The combined experiments of 12C irradiation together with 
TEM and GEM revealed independent toxicities and no additive 
or even supra-additive effects (Figures 5 and 6).
DiscUssiOn
The results for the combination of 12C and both tested systemic 
substances TEM and GEM showed independent toxicities in all 
cell lines, whereas the combination of photon beams showed 
supra-additivity for the PLC cell line as defined using the isobolo-
gram method of Steel and Peckham (13). The same effect was 
seen for HuH7 cells treated with photon beams and TEM. In all 
other cell lines and combinations, only independent toxicities 
were observed. Some of the survival curves after 12C irradiation 
showed an upward tailing, which cannot be explained by the 
linear-quadratic mode. However, it is known that experimental 
data from high-LET radiation do not always fit to the linear-
quadratic model (15). Using our special experimental setup, the 
results could not be merely explained as unattached mitotic cells 
not reached by high LET particles. It is known that high LET 
radiations increase also the complexity of lesions due to the for-
mation of multiply damaged sites. However, the linear-quadratic 
model did not relate to this important aspect (15).
Until now, RT as a single modality has not played an important 
role for the treatment of HCC, since the liver tolerance to RT is 
poor (16). Many technical improvements in conformal RT, such 
as IMRT and PBT, have led to better dose distributions and war-
rant better sparing of the surrounding tissue (17). Many studies 
FigUre 3 | Fitted survival curves of hepg2, hep3B, huh7, and Plc cells after combined modality treatment with photon irradiation and 
Temsirolimus. Abbreviations: TEM, Temsirolimus; GEM, Gemcitabine. Error bars represent SD. The dashed line presents the predicted survival curve for TEM or 
GEM plus radiation, which was corrected for drug toxicity by normalizing the survival curve to the corresponding non-irradiated control group.
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on SBRT and PBT in HCC patients demonstrated encouraging 
results (5, 17). With the implementation of PBT, 12C beams 
give hope of improved tumor responses to irradiation. Carbon 
ion beams have additional biological advantages compared to 
protons or X-rays, decreased oxygen enhancement ratio, reduced 
cell cycle-dependency and the potential of metastases suppres-
sion (18, 19). Because of its physical and biological advantages, 
12C RT is a promising modality in the treatment of patients with 
HCC. This was confirmed by in vitro experiments of our group 
with rectal, pancreatic, and lung cancer cells showing that carbon 
beam ion beams exert a high RBE (20–23). Experimental data on 
the efficacy of heavy ions including 12C and 16O in HCC cell lines 
are encouraging. Recently, an enhanced RBE for 12C and 16O in 
these cell lines was shown by our group (24).
Several studies of 12C RT in HCC patients have been launched. 
Recently, preliminary results of a phase-I clinical trial evaluating 
12C RT in HCC patients were reported (25, 26). Patients were 
irradiated with 4 ×  10  Gy (RBE) without experiencing severe 
7Dehne et al. Combined Modality Treatment in HCC
Frontiers in Oncology | www.frontiersin.org March 2017 | Volume 7 | Article 35
adverse effects during follow-up. No local relapse was observed 
during the follow-up period. Komatsu et al. performed a further 
study on 343 patients with 386 tumors of which 101 patients with 
106 tumors received carbon ion therapy (17). Median follow-up 
was 31.0 months and the 5 years local control rates for patients 
receiving 12C treatment was 93%. Finally, available clinical stud-
ies on 12C RT in HCC patients demonstrate an overall safe and 
efficient therapy and may be an alternative to standard treatments 
a selected patient group.
Since treatment of locally advanced or metastatic HCC is still 
challenging and unsatisfactory, several systemic drugs have been 
tested for patients presenting with late stage disease. Among these 
there is GEM having shown broad activity against a variety of 
solid tumors, especially in hepatobiliary malignancies (11, 12, 27). 
GEM is a cytidine analog, which is phosphorylated to the active 
nucleotides gemcitabine diphosphate (dFdCDP) and triphosphate 
(dFdCTP). The anti-proliferative activity is mediated by various 
mechanisms. Preclinical studies demonstrated strong activity of 
FigUre 4 | Fitted survival curves of hepg2, hep3B, huh7, and Plc cells after combined modality treatment with photon irradiation and 
gemcitabine. Abbreviations: TEM, Temsirolimus; GEM, Gemcitabine. Error bars represent SD. Error bars represent SD. The dashed line presents the predicted 
survival curve for 10 nM GEM plus radiation, while the dotted line presents the predicted survival curve for 30 nM GEM plus radiation, which was corrected for drug 
toxicity by normalizing the survival curve to the corresponding non-irradiated control group.
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GEM against HepG2 cells with an inhibition constant of about 
3.98nM (28). This is consistent with the results of this work where 
an IC50 value is achieved at a concentration of around 20nM in 
HepG2 cells after an incubation period of 4 h. Therefore, it has to 
be taken into account that the incubation time of the experiments 
of Graziadei et al. was clearly longer (96 h) than ours. The IC50 
values of our experiments using Hep3B, PLC, and HuH7 ranged 
from 19 to 50nM. Unfortunately, following phase II clinical trials 
with single agent GEM showed only marginal activity in HCC 
with response rates between 0 and 20% (29–31). Combination 
of photons and GEM revealed independent toxicities for all cell 
lines except for PLC cells, for which supra-additive effects were 
demonstrated.
Another developing strategy of treatment of advanced HCC 
is the therapy with molecular targeting drugs interfering with 
distinct pathways of carcinogenesis. TEM is one of them target-
ing mammalian target of rapamycin (mTOR) that is a part of the 
PI3K/Akt/mTOR-pathway, whose aberrant activation has been 
shown to be an important mechanism in the malignant trans-
formation in HCC (9). This pathway is activated by binding of 
FigUre 5 | Fitted survival curves of hepg2, hep3B, huh7, and Plc cells after combined modality treatment with 12c irradiation and Temsirolimus. 
Abbreviations: TEM, Temsirolimus; GEM, Gemcitabine. Error bars represent SD.
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growth factors (i.e., EGFR, VEGFR, PDGFR, and IGFR) to the 
membrane receptor thus leading to PI3K-activation, which in 
turn downstream activates effectors such as Akt and mTOR. It 
could be shown that approximately 50% of HCC demonstrate 
aberrant mTOR activation (32). Inhibition of mTOR blocks 
key signal transduction pathways regulated by p70s6 and 
the eukaryotic initiation factor 4E-binding protein (4E-BP1). 
This does not only result in cell cycle arrest at G1 but also in 
reduced proliferation, impaired angiogenesis, and improved 
survival (32, 33). Moreover, TEM interacts with proteins like 
BAD, Bcl2, and p53 regulating apoptosis resulting in a shift 
of balance toward apoptosis. The four analyzed HCC cell lines 
showed different responses after treatment with TEM. HUH7 
and PLC seem to be much more sensitive than Hep3B and 
HepG2 (IC50  =  0.22nM for HUH7; IC50  =  0.4nM for PLC; 
IC50 = 190nM for HepG2; IC50 = 210nM for Hep3B). Our find-
ings are consistent with experiments by Zhou et al. in principle 
(34). They performed in vitro experiments with HUH7, Hep3B, 
PLC, and HepG2 and demonstrated IC50 values of 1.27μM for 
HUH7, 8.77μM for HepG2, 11.21μM for PLC, and 52.95μM 
for Hep3b after an incubation time of 24 h showing HUH7 to 
be the most sensitive cell line. Recently, two phase-I and -II 
FigUre 6 | Fitted survival curves of hepg2, hep3B, huh7, and Plc cells after combined modality treatment with 12c irradiation and gemcitabine. 
Abbreviations: TEM, Temsirolimus; GEM, Gemcitabine. Error bars represent SD.
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studies on the efficiency of mToR-directed targeted substances 
Everolimus and Sirolimus showed only modest activity in 
advanced HCC (35, 36).
Since combination of TEM and RT in HCC has not been 
investigated yet, we performed in  vitro studies on TEM with 
either photon or 12C RT. The combination of both showed 
supra-additive effects on HuH7 and PLC cells, whereas a small 
response was seen in Hep3B. HepG2 cells tendentially exhibit 
supra-additive effects on cell survival but due to overlapping SDs 
no clear point can be made. Therefore, we classified the observed 
effects as independent toxicity. Comparing this to monotherapy 
with TEM similar tendencies can be seen with PLC and HUH7 
being the most sensitive cells, while Hep3B cells showed minimal 
effects. The results mentioned above lead to the conclusion that 
TEM radio-sensitizes HuH7 and PLC cells, whereas this effect 
was not observed for HepG2 and Hep3B cells.
Regarding the combination of 12C beams either with TEM 
or GEM, all cell lines exhibit independent toxicities. It can be 
assumed that combining 12C with systemic substances only has 
independent effects because heavy ions cause direct damage 
because of their high-LET character resulting in clustered DSBs. 
These DSBs are the most lethal molecular injuries that can be 
done to DNA, and therefore, addition of systemic drugs should 
not lead to radiosensitizing effects (20). Nonetheless, further 
investigations are warranted in order to determine whether addi-
tion of systemic therapy allows a reduction of radiation doses in 
combination therapy. This could possibly lead to better responses 
and tolerances in patients with HCC.
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